Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
Michopoulos
Spyros
S
Gastroenterology Unit, Alexandra Hospital, Athens, Greece.
Petraki
Kalliopi
K
Matsouka
Charis
C
Kastritis
Efstathios
E
Chrysanthopoulou
Heleni
H
Dimopoulos
Meletios Athanasios
MA
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D005770:Gastrointestinal Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D020522:Lymphoma, Mantle-Cell / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D011719:Pyrazines; D000069283:Rituximab; D014750:Vincristine; D000069286:Bortezomib; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone